激酶
体内
化学
前列腺癌
药理学
生物利用度
小分子
药代动力学
体外
共价键
癌症研究
离体
铅化合物
前列腺
生物化学
癌症
共价结合
DNA损伤
药物发现
选择性
磷酸化
机制(生物学)
转录因子
计算生物学
作者
Kaijie Zhou,Licheng Zhou,Jean Ching-Yi Tien,Weixue Huang,Wenyan Liu,Xinyu Sun,Bohai Fan,Xin Huang,Jun Wang,Yu Chang,Jianzhang Yang,Yue Yin,Chen Su,Qingrun Li,Rahul Mannan,Somnath Mahapatra,Yunhui Cheng,Abigail J. Todd,Christina E. Wheeler,Shuqin Li
标识
DOI:10.1016/j.apsb.2026.07.041
摘要
Previous studies highlight the therapeutic promise of inhibiting cyclin-dependent kinases 12 and 13 (CDK12/13) for castration-resistant prostate cancer (CRPC) and other malignancies. However, developing small molecule modulators of CDK12/13 that exhibit an optimal combination of potency, selectivity and favorable pharmacokinetics (PK) remains challenging. In this study, we present ZLC853 , a potent, selective, and orally bioavailable covalent inhibitor of CDK12/13 developed through PK-oriented optimization of our previously reported inhibitor YJZ5118. ZLC853 potently inhibited CDK12 and CDK13 with IC 50 values of 40.0 and 18.2 nmol/L, respectively, and displayed exceptional kinase selectivity in a comprehensive KinomeScan assay. Its covalent binding mechanism was unequivocally validated through mass spectrometry, co-crystal structure analysis, cellular pull-down assays, and washout experiments. Functionally, ZLC853 suppressed the transcription of DNA damage response genes, induced DNA damage, and promoted apoptosis. Additionally, ZLC853 exhibited good oral bioavailability and robust antitumor activity across multiple prostate cancer models, both in vitro and in vivo , supporting it as a promising candidate for clinical investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI